FDASIA Study Mandates Focus On Performance, But Could Slow Reviews
Executive Summary
Advocates for the agency worry that while each of the performance assessments seems reasonable individually, together the reports could burden staff to the point of pulling some from application reviews or other tasks to help complete them.
You may also be interested in...
Warnings Up As US FDA Trims List Of Uninspected OTC Drug Manufacturers
Hundreds of foreign firms making OTC drugs marketed in US had not been inspected for GMPs compliance before FDA Safety and Innovation Act pointed agency toward crossing those facilities off its list. Of the foreign OTC facilities inspected between June 2016 and Jan. 9, 2018, 25% received "official action indicated" inspection results, driving warning letters and import alerts.
Warnings Up As FDA Trims Its List Of Uninspected OTC Drug Manufacturers
Hundreds of foreign OTC drug firms marketing products in US had not been inspected for GMP compliance before FDA Safety and Innovation Act of 2012 pointed agency toward crossing those facilities off its list. Of the foreign OTC facilities inspected between June 2016 and January 2018, 25% received "official action indicated" inspection results, prompting warning letters and import alerts.
Priority Review Voucher Extension Scaled Back In New Cures Bill
Pediatric rare disease program would have been renewed for seven years under previous draft, but now would only have a three-year on life as full committee mark-up begins.